

23 Oct 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J and Roche's first-half wins and challenges; Alexion's Ultomiris plans; GSK's AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 October 2022, including: [\*Johnson & Johnson\*](#) and [\*Roche Holding AG\*](#)'s first-half wins and challenges; [\*Alexion Pharmaceuticals Inc.\*](#)'s Ultomiris plans; [\*GSK plc\*](#)'s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

This and all our other podcasts are available on the Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway\*](#)" - Scrip, 18 Oct, 2022.)

(Also see "[\*Vabysmo Is Bright Spot For Roche In Bumpy Q3\*](#)" - Scrip, 18 Oct, 2022.)

(Also see "[\*Alexion's Ultomiris Expands Its Reach As Soliris Biosimilars Loom\*](#)" - Scrip, 17 Oct, 2022.)

(Also see "[\*GSK's New Research Chief Begins Leadership With Expanded Genomics/AI Alliance\*](#)" - Scrip, 18 Oct, 2022.)

(Also see "[\*US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin\*](#)" - Scrip, 17 Oct, 2022.)

[\*Click here to explore this interactive content online\*](#) ✎